Callan Capital LLC Reduces Stock Position in Zoetis Inc. (NYSE:ZTS)

Callan Capital LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,827 shares of the company’s stock after selling 174 shares during the period. Callan Capital LLC’s holdings in Zoetis were worth $461,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ZTS. AMF Tjanstepension AB increased its holdings in shares of Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after purchasing an additional 20,001 shares during the period. Howard Capital Management Group LLC increased its holdings in shares of Zoetis by 0.8% in the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after purchasing an additional 883 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Zoetis by 8.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 55,696 shares of the company’s stock worth $10,882,000 after purchasing an additional 4,107 shares during the period. International Assets Investment Management LLC increased its holdings in shares of Zoetis by 41,235.7% in the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after purchasing an additional 937,700 shares during the period. Finally, Mount Yale Investment Advisors LLC increased its holdings in shares of Zoetis by 3.1% in the third quarter. Mount Yale Investment Advisors LLC now owns 4,503 shares of the company’s stock worth $880,000 after purchasing an additional 137 shares during the period. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ZTS. Piper Sandler decreased their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Stifel Nicolaus dropped their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $215.40.

Zoetis Stock Performance

Shares of ZTS opened at $160.39 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The company has a 50-day simple moving average of $166.51 and a two-hundred day simple moving average of $177.99. The firm has a market capitalization of $71.82 billion, a PE ratio of 29.32, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.